Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen RJ, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394:24 de octubre. [Ref.ID 103199]

Byrne P, Cullinan J, Smith S. Statins for primary prevention of cardiovascular disease. BMJ 2019;367:16 de octubre. [Ref.ID 103197]

Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S, COMPASS Investigators. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 2019;157:agosto. [Ref.ID 103177]

Hartholt KA, Lee R, Burns ER, van Beeck EF. Mortality from falls among US adults aged 75 years or older, 2000-2016. JAMA 2019;321:4 de junio. [Ref.ID 103174]

Pinto T. Los nuevos anticoagulantes obligan a las farmacéuticas a pagar cientos de millones para evitar juicios . eldiario.es 2019:31 de marzo. [Ref.ID 103065]

Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events. A systematic review and meta-analysis. JAMA 2019;321:22 de enero. [Ref.ID 103021]

Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, for the VITAL Research Group. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 2019;380:3 de enero. [Ref.ID 102995]

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM, for the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:3 de enero. [Ref.ID 102994]

Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J, Groeneveld PW. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016. JAMA Intern Med 2018;178:julio. [Ref.ID 102882]

Richman IB, Ross JS. Weighing the harms and benefits of using statins for primary prevention: raising the risk threshold. Ann Intern Med 2018:4 de diciembre. [Ref.ID 102877]

Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, for the VITAL Research Group. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 2018:10 de noviembre. [Ref.ID 102848]

The ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102845]

The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102844]

McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton CB, Brauer D, Cloud G, Wood EM, Mahady SE, Satterfield S, Grimm R, Murray AM, for the ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102843]

McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, Storey E, Shah RC, Lockery JE, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Ryan J, Radziszewska B, Grimm R, Murray AM, for the ASPREE Investigator Group. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102842]

Goldenberg JZ, Mertz D, Johnston BC. Probiotics to prevent Clostridium difficile Infection in patients receiving antibiotics. JAMA 2018;320:7 de agosto. [Ref.ID 102829]

Navarese EP, Robinson JG, Kowatewski M, Kotodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering. A systematic review and meta-analysis. JAMA 2018;319:17 de abril. [Ref.ID 102784]

Navar AM, Peterson ED. Challenges in interpreting the lipid-lowering trials: biology vs ecology. JAMA 2018;319:17 de abril. [Ref.ID 102783]

Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY, for the Clinical Research Collaboration Neurological Emergencies Treatment Trials Network and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;379:19 de julio. [Ref.ID 102746]

Rothwell PPM, Cook PNR, Gaziano PJM, Price JF, Belch PJFF, Roncaglioni MC, Morimoto T, Mehta Z. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018:12 de julio. [Ref.ID 102745]